Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129
September 11, 2017 08:00 ET
|
Atara Biotherapeutics, Inc.
Health Canada New Drug Submission (NDS) planned based on Phase 1 and 2 clinical results and supported by available data from anticipated MATCH and ALLELE Phase 3 studies, which are expected to be...
Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230
September 05, 2017 08:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics to Participate in Three Upcoming Investor Conferences
August 31, 2017 16:15 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
August 22, 2017 16:34 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer
August 22, 2017 08:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights
August 07, 2017 16:05 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
August 02, 2017 08:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS)
July 31, 2017 08:09 ET
|
Atara Biotherapeutics, Inc.
New results characterizing the molecular signature of Epstein-Barr Virus (EBV) in MS brain lesions will also be presented Presentations to take place during the upcoming MSParis2017 Congress, the 7th...
Atara Biotherapeutics to Present at Three Upcoming Investor Conferences
May 24, 2017 08:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the Company will present at three upcoming investor conferences in June: ...
Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2017 17:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the compensation committee of Atara’s board of directors, approved a...